SG11201810967VA - Radio-pharmaceutical complexes - Google Patents
Radio-pharmaceutical complexesInfo
- Publication number
- SG11201810967VA SG11201810967VA SG11201810967VA SG11201810967VA SG11201810967VA SG 11201810967V A SG11201810967V A SG 11201810967VA SG 11201810967V A SG11201810967V A SG 11201810967VA SG 11201810967V A SG11201810967V A SG 11201810967VA SG 11201810967V A SG11201810967V A SG 11201810967VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- targeting
- tissue
- oslo
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16173874 | 2016-06-10 | ||
| PCT/EP2017/063689 WO2017211809A1 (en) | 2016-06-10 | 2017-06-06 | Radio-pharmaceutical complexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810967VA true SG11201810967VA (en) | 2019-01-30 |
Family
ID=56132786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810967VA SG11201810967VA (en) | 2016-06-10 | 2017-06-06 | Radio-pharmaceutical complexes |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20190298865A1 (ja) |
| EP (1) | EP3468619A1 (ja) |
| JP (1) | JP2019517547A (ja) |
| KR (1) | KR20190016544A (ja) |
| CN (1) | CN109689115A (ja) |
| AR (1) | AR110466A1 (ja) |
| AU (1) | AU2017277463A1 (ja) |
| BR (1) | BR112018075554A2 (ja) |
| CA (1) | CA3026900A1 (ja) |
| CL (1) | CL2018003550A1 (ja) |
| CO (1) | CO2018013359A2 (ja) |
| CR (1) | CR20180581A (ja) |
| CU (1) | CU20180149A7 (ja) |
| DO (1) | DOP2018000277A (ja) |
| EA (1) | EA201892814A1 (ja) |
| EC (1) | ECSP18091468A (ja) |
| IL (1) | IL263538A (ja) |
| MA (1) | MA45225A (ja) |
| MX (1) | MX2018015340A (ja) |
| NI (1) | NI201800136A (ja) |
| PE (1) | PE20190327A1 (ja) |
| PH (1) | PH12018502605A1 (ja) |
| SG (1) | SG11201810967VA (ja) |
| TW (1) | TW201805025A (ja) |
| UY (1) | UY37286A (ja) |
| WO (1) | WO2017211809A1 (ja) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| KR102398439B1 (ko) | 2016-03-07 | 2022-05-16 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| TWI811236B (zh) | 2017-08-28 | 2023-08-11 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
| WO2019143902A2 (en) | 2018-01-22 | 2019-07-25 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| UY38383A (es) | 2018-09-21 | 2020-04-30 | Enanta Pharm Inc | Heterociclos funcionalizados como agentes antivirales |
| KR20210093951A (ko) | 2018-11-21 | 2021-07-28 | 이난타 파마슈티칼스, 인코포레이티드 | 항바이러스제로서의 작용화된 헤테로사이클 |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| MX2022000252A (es) | 2019-07-08 | 2022-02-21 | 3B Pharmaceuticals Gmbh | Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo. |
| EP3763726A1 (en) | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| US20220315554A1 (en) | 2019-07-08 | 2022-10-06 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| AR119479A1 (es) | 2019-07-25 | 2021-12-22 | Bayer As | Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| KR20230093251A (ko) | 2020-09-10 | 2023-06-27 | 프리시릭스 엔.브이. | Fap에 대한 항체 단편 |
| AU2022205523A1 (en) | 2021-01-07 | 2023-07-13 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EP4050018A1 (en) | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4880615A (en) | 1988-11-25 | 1989-11-14 | Merck & Co., Inc. | Stabilized radiopharmaceutical compositions |
| US5624901A (en) | 1994-04-15 | 1997-04-29 | The Regents Of The University Of California | 3-hydroxy-2(1H)-pyridinone chelating agents |
| NO312708B1 (no) | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
| NO313180B1 (no) | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| EP2423201B1 (en) | 2006-08-15 | 2017-10-04 | The Regents of the University of California | Luminescent macrocyclic lanthanide complexes |
| WO2011040972A1 (en) | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| WO2011079291A1 (en) * | 2009-12-24 | 2011-06-30 | Lumiphore, Inc. | Radiopharmaceutical complexes |
| GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201208309D0 (en) | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
| NL2009131C2 (en) * | 2012-07-05 | 2014-01-07 | Stichting Vu Vumc | Compound and use of compound to prepare a radiollabelled compound. |
| MA41176A (fr) * | 2014-12-17 | 2017-10-24 | Bayer As | Complexes radio-pharmaceutiques |
-
2017
- 2017-06-06 CN CN201780049257.8A patent/CN109689115A/zh active Pending
- 2017-06-06 CU CU2018000149A patent/CU20180149A7/es unknown
- 2017-06-06 CR CR20180581A patent/CR20180581A/es unknown
- 2017-06-06 MX MX2018015340A patent/MX2018015340A/es unknown
- 2017-06-06 CA CA3026900A patent/CA3026900A1/en not_active Abandoned
- 2017-06-06 WO PCT/EP2017/063689 patent/WO2017211809A1/en unknown
- 2017-06-06 US US16/308,307 patent/US20190298865A1/en not_active Abandoned
- 2017-06-06 MA MA045225A patent/MA45225A/fr unknown
- 2017-06-06 EA EA201892814A patent/EA201892814A1/ru unknown
- 2017-06-06 PE PE2018003200A patent/PE20190327A1/es unknown
- 2017-06-06 KR KR1020197000406A patent/KR20190016544A/ko unknown
- 2017-06-06 JP JP2018564263A patent/JP2019517547A/ja active Pending
- 2017-06-06 AU AU2017277463A patent/AU2017277463A1/en not_active Abandoned
- 2017-06-06 EP EP17729086.3A patent/EP3468619A1/en not_active Withdrawn
- 2017-06-06 BR BR112018075554A patent/BR112018075554A2/pt not_active Application Discontinuation
- 2017-06-06 SG SG11201810967VA patent/SG11201810967VA/en unknown
- 2017-06-09 TW TW106119188A patent/TW201805025A/zh unknown
- 2017-06-09 UY UY0001037286A patent/UY37286A/es not_active Application Discontinuation
- 2017-06-09 AR ARP170101585A patent/AR110466A1/es unknown
-
2018
- 2018-12-06 IL IL263538A patent/IL263538A/en unknown
- 2018-12-10 DO DO2018000277A patent/DOP2018000277A/es unknown
- 2018-12-10 PH PH12018502605A patent/PH12018502605A1/en unknown
- 2018-12-10 NI NI201800136A patent/NI201800136A/es unknown
- 2018-12-10 CO CONC2018/0013359A patent/CO2018013359A2/es unknown
- 2018-12-10 EC ECSENADI201891468A patent/ECSP18091468A/es unknown
- 2018-12-10 CL CL2018003550A patent/CL2018003550A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2018003550A1 (es) | 2019-02-01 |
| JP2019517547A (ja) | 2019-06-24 |
| EP3468619A1 (en) | 2019-04-17 |
| PE20190327A1 (es) | 2019-03-05 |
| MX2018015340A (es) | 2019-03-28 |
| US20190298865A1 (en) | 2019-10-03 |
| AR110466A1 (es) | 2019-04-03 |
| CO2018013359A2 (es) | 2018-12-14 |
| NI201800136A (es) | 2019-04-29 |
| PH12018502605A1 (en) | 2019-10-21 |
| IL263538A (en) | 2019-01-31 |
| CN109689115A (zh) | 2019-04-26 |
| DOP2018000277A (es) | 2018-12-31 |
| EA201892814A1 (ru) | 2019-06-28 |
| TW201805025A (zh) | 2018-02-16 |
| WO2017211809A1 (en) | 2017-12-14 |
| ECSP18091468A (es) | 2018-12-31 |
| MA45225A (fr) | 2019-04-17 |
| UY37286A (es) | 2018-01-31 |
| CA3026900A1 (en) | 2017-12-14 |
| KR20190016544A (ko) | 2019-02-18 |
| BR112018075554A2 (pt) | 2019-10-01 |
| AU2017277463A1 (en) | 2019-01-03 |
| CU20180149A7 (es) | 2019-07-04 |
| CR20180581A (es) | 2019-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810967VA (en) | Radio-pharmaceutical complexes | |
| SG11201908131RA (en) | Benzazepine compounds, conjugates, and uses thereof | |
| SG11201807187XA (en) | Binding members to pd-l1 | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201811338VA (en) | A novel botulinum neurotoxin and its derivatives | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201811706RA (en) | Process for the preparation of microcapsules | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201805680SA (en) | Methods and compositions for the treatment of neurologic disease | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers |